- $14.31m
- $10.04m
- 29
- 14
- 55
- 24
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.45 | ||
| Price to Tang. Book | 3.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -148.88% | ||
| Return on Equity | -95.77% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Sep | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.41 | 0.33 | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Edesa Biotech, Inc. is a Canada-based clinical-stage biopharmaceutical company developing various ways to treat inflammatory and immune-related diseases. The Company’s advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. It is evaluating EB05 in a Phase III study as a potential treatment for acute respiratory distress syndrome (ARDS), a life-threatening form of respiratory failure. In addition, the Company is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic allergic contact dermatitis (ACD), a common occupational skin condition. It is conducting a Phase II trial of its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. The Company is also developing product candidates for a number of chronic dermatological and inflammatory conditions.
Directors
- Sean Macdonald NEC (45)
- Michael Brooks PRE (43)
- Pardeep Nijhawan CEO (51)
- Kathi Niffenegger CFO (64)
- Frank Oakes DRC (71)
- Lorin Johnson IND (69)
- Paul Pay IND (67)
- Carlo Sistilli IND (65)
- Peter van der Velden IND (60)
- Last Annual
- September 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 25th, 2009
- Public Since
- August 25th, 2008
- No. of Shareholders
- 13
- No. of Employees
- 16
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 3,215,968
- Address
- 100 Spy Crt, MARKHAM, L3R 5H6
- Web
- https://www.edesabiotech.com/
- Phone
- +1 9054751234
- Auditors
- MNP LLP
Upcoming Events for EDSA
Edesa Biotech Inc Annual Shareholders Meeting
Edesa Biotech Inc Annual Shareholders Meeting
Edesa Biotech Inc Extraordinary Shareholders Meeting
Q3 2024 Edesa Biotech Inc Earnings Release
Similar to EDSA
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Edesa Biotech share price?
As of Today at 19:07 UTC, shares in Edesa Biotech are trading at $4.45. This share price information is delayed by 15 minutes.
How has the Edesa Biotech share price performed this year?
Shares in Edesa Biotech last closed at $4.45 and the price had moved by -39.46% over the past 365 days. In terms of relative price strength the Edesa Biotech share price has underperformed the S&P500 Index by -49.62% over the past year.
What are the analyst and broker recommendations for Edesa Biotech?
The overall consensus recommendation for Edesa Biotech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Edesa Biotech dividend yield?
Edesa Biotech does not currently pay a dividend.
Does Edesa Biotech pay a dividend?
Edesa Biotech does not currently pay a dividend.
When does Edesa Biotech next pay dividends?
Edesa Biotech does not currently pay a dividend.
How do I buy Edesa Biotech shares?
To buy shares in Edesa Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Edesa Biotech?
As of the previous close price of $4.45, shares in Edesa Biotech had a market capitalisation of $14.31m.
Where are Edesa Biotech shares listed?
Here are the trading details for Edesa Biotech:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: EDSA
What kind of share is Edesa Biotech?
Based on an overall assessment of its quality, value and momentum Edesa Biotech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Edesa Biotech share price forecast for 2024?
The analyst consensus target price for shares in Edesa Biotech is $24.00. That is 439.33% above the last closing price of $4.45.
Analysts covering Edesa Biotech currently have a consensus Earnings Per Share (EPS) forecast of -$2.32 for the next financial year.
What is the trend in the Edesa Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Edesa Biotech. Over the past six months, its share price has outperformed the S&P500 Index by +9.83%.
As of the last closing price of $4.45, shares in Edesa Biotech were trading -6.34% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Edesa Biotech PE Ratio?
The Edesa Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Edesa Biotech?
Edesa Biotech's management team is headed by:
- Sean Macdonald - NEC
- Michael Brooks - PRE
- Pardeep Nijhawan - CEO
- Kathi Niffenegger - CFO
- Frank Oakes - DRC
- Lorin Johnson - IND
- Paul Pay - IND
- Carlo Sistilli - IND
- Peter van der Velden - IND